MA38155B1 - Utilisation du pidotimod pour traiter le psoriasis - Google Patents
Utilisation du pidotimod pour traiter le psoriasisInfo
- Publication number
- MA38155B1 MA38155B1 MA38155A MA38155A MA38155B1 MA 38155 B1 MA38155 B1 MA 38155B1 MA 38155 A MA38155 A MA 38155A MA 38155 A MA38155 A MA 38155A MA 38155 B1 MA38155 B1 MA 38155B1
- Authority
- MA
- Morocco
- Prior art keywords
- pidotimod
- treat psoriasis
- psoriasis
- acceptable salt
- physiologically acceptable
- Prior art date
Links
- UUTKICFRNVKFRG-WDSKDSINSA-N (4R)-3-[oxo-[(2S)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic acid Chemical compound OC(=O)[C@@H]1CSCN1C(=O)[C@H]1NC(=O)CC1 UUTKICFRNVKFRG-WDSKDSINSA-N 0.000 title abstract 3
- 201000004681 Psoriasis Diseases 0.000 title abstract 3
- 229960001163 pidotimod Drugs 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention porte sur l'utilisation du pidotimod ou de son sel physiologiquement acceptable pour traiter le psoriasis. Dans l'invention, le pidotimod ou son sel physiologiquement acceptable peut être administré par voie systémique ou topique pour traiter le psoriasis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/076088 WO2014094840A1 (fr) | 2012-12-19 | 2012-12-19 | Utilisation du pidotimod pour traiter le psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA38155A1 MA38155A1 (fr) | 2016-02-29 |
| MA38155B1 true MA38155B1 (fr) | 2016-09-30 |
Family
ID=47520054
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38155A MA38155B1 (fr) | 2012-12-19 | 2012-12-19 | Utilisation du pidotimod pour traiter le psoriasis |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US20150328191A1 (fr) |
| EP (1) | EP2934521B1 (fr) |
| JP (1) | JP6051315B2 (fr) |
| KR (1) | KR20150095773A (fr) |
| CN (1) | CN104869994B (fr) |
| AR (1) | AR094027A1 (fr) |
| AU (1) | AU2012396942A1 (fr) |
| BR (1) | BR112015011391A2 (fr) |
| CA (1) | CA2887878A1 (fr) |
| CY (1) | CY1118645T1 (fr) |
| DK (1) | DK2934521T3 (fr) |
| EA (1) | EA201591185A1 (fr) |
| ES (1) | ES2617235T3 (fr) |
| HK (1) | HK1210937A1 (fr) |
| HR (1) | HRP20161666T1 (fr) |
| HU (1) | HUE031846T2 (fr) |
| IL (1) | IL239429A0 (fr) |
| LT (1) | LT2934521T (fr) |
| MA (1) | MA38155B1 (fr) |
| ME (1) | ME02560B (fr) |
| MX (1) | MX2015008104A (fr) |
| PH (1) | PH12015501210A1 (fr) |
| PL (1) | PL2934521T3 (fr) |
| PT (1) | PT2934521T (fr) |
| RS (1) | RS55436B1 (fr) |
| SG (1) | SG11201503270UA (fr) |
| SI (1) | SI2934521T1 (fr) |
| SM (2) | SMT201700072T1 (fr) |
| TN (1) | TN2015000142A1 (fr) |
| WO (1) | WO2014094840A1 (fr) |
| ZA (1) | ZA201502573B (fr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015036009A1 (fr) * | 2013-09-10 | 2015-03-19 | Polichem S.A. | Pidotimod à utiliser dans le traitement de maladies associées à une inflammation |
| EP3436477A2 (fr) | 2016-03-29 | 2019-02-06 | Janssen Biotech, Inc. | Methode de traitement du psoriasis avec dosage intervalle augmenté d'anticorps anti-il12 et/ou -23 |
| CN105943505A (zh) * | 2016-05-26 | 2016-09-21 | 杭州百诚医药科技股份有限公司 | 一种匹多莫德药物组合物及其制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231723B (it) | 1989-08-11 | 1991-12-21 | Poli Ind Chimica Spa | Derivati dell'acido piroglutammico, loro preparazioni e composizioni farmaceutiche che li contengono |
| US5594015A (en) * | 1994-06-22 | 1997-01-14 | Regents Of The University Of California | Thiazolidine derivatives for the treatment of psoriasis |
| WO2003018011A1 (fr) * | 2001-08-24 | 2003-03-06 | Wyeth Holdings Corporation | 5-(substitue)-5-(substitue sulfonyl ou sulfanyl)thiazolidine-2,4-diones utiles pour l'inhibition de la farnesyl-proteine transferase |
-
2012
- 2012-12-19 SI SI201230870A patent/SI2934521T1/sl unknown
- 2012-12-19 CN CN201280076628.9A patent/CN104869994B/zh active Active
- 2012-12-19 HK HK15111635.1A patent/HK1210937A1/xx unknown
- 2012-12-19 SG SG11201503270UA patent/SG11201503270UA/en unknown
- 2012-12-19 LT LTEP12812221.5T patent/LT2934521T/lt unknown
- 2012-12-19 HR HRP20161666TT patent/HRP20161666T1/hr unknown
- 2012-12-19 US US14/652,482 patent/US20150328191A1/en not_active Abandoned
- 2012-12-19 PT PT128122215T patent/PT2934521T/pt unknown
- 2012-12-19 EP EP12812221.5A patent/EP2934521B1/fr active Active
- 2012-12-19 RS RS20161102A patent/RS55436B1/sr unknown
- 2012-12-19 SM SM20170072T patent/SMT201700072T1/it unknown
- 2012-12-19 JP JP2015548221A patent/JP6051315B2/ja not_active Expired - Fee Related
- 2012-12-19 CA CA2887878A patent/CA2887878A1/fr not_active Abandoned
- 2012-12-19 DK DK12812221.5T patent/DK2934521T3/en active
- 2012-12-19 HU HUE12812221A patent/HUE031846T2/hu unknown
- 2012-12-19 ES ES12812221.5T patent/ES2617235T3/es active Active
- 2012-12-19 PL PL12812221T patent/PL2934521T3/pl unknown
- 2012-12-19 BR BR112015011391A patent/BR112015011391A2/pt not_active IP Right Cessation
- 2012-12-19 ME MEP-2016-277A patent/ME02560B/fr unknown
- 2012-12-19 MA MA38155A patent/MA38155B1/fr unknown
- 2012-12-19 KR KR1020157018215A patent/KR20150095773A/ko not_active Withdrawn
- 2012-12-19 MX MX2015008104A patent/MX2015008104A/es unknown
- 2012-12-19 EA EA201591185A patent/EA201591185A1/ru unknown
- 2012-12-19 WO PCT/EP2012/076088 patent/WO2014094840A1/fr not_active Ceased
- 2012-12-19 AU AU2012396942A patent/AU2012396942A1/en not_active Abandoned
-
2013
- 2013-12-16 AR ARP130104757A patent/AR094027A1/es unknown
-
2015
- 2015-04-14 TN TNP2015000142A patent/TN2015000142A1/fr unknown
- 2015-04-16 ZA ZA2015/02573A patent/ZA201502573B/en unknown
- 2015-05-29 PH PH12015501210A patent/PH12015501210A1/en unknown
- 2015-06-15 IL IL239429A patent/IL239429A0/en unknown
-
2017
- 2017-01-30 SM SM201700072T patent/SMT201700072B/it unknown
- 2017-02-21 CY CY20171100232T patent/CY1118645T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201692271A1 (ru) | Терапевтически активные соединения и способы их применения | |
| MX2015010921A (es) | Compuestos de carbazol utiles como inhibidores de bromodominio. | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
| EP2654745A4 (fr) | Composition pour le traitement d'états pathologiques de la peau | |
| NZ708453A (en) | Germicidal compositions comprising carboxylic acid mixture and use as topical disinfectants | |
| EA032271B9 (ru) | Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний | |
| IN2014DN09228A (fr) | ||
| EP2827847A4 (fr) | Complexes contenant du strontium administré par voie topique pour le traitement de la douleur, du prurit et de l'inflammation | |
| MA38253B1 (fr) | Compositions comprenant de la vortioxétine et du donépézil | |
| CL2012001293A1 (es) | Uso del compuesto 2-(4-metilfenil)-6-(metil)quinolina para inhibor la agragacion de la proteina tau en una persona dque sufre alzheimer | |
| EA201290808A1 (ru) | Замещенные конденсированные производные имидазола, фармацевтические композиции и способы их применения | |
| EP2938342A4 (fr) | Composés d'indole pour utilisation dans le traitement de l'inflammation et du cancer | |
| MA38155A1 (fr) | Utilisation du pidotimod pour traiter le psoriasis | |
| EA201490938A1 (ru) | Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем | |
| EP2578215A4 (fr) | Utilisation d'oxaloacétate pour le traitement de l'ischémie | |
| EP2838508A4 (fr) | Formulations et procédés pour le traitement de l'acné et d'affections cutanées inflammatoires | |
| AU2014365665A1 (en) | Use of PAR-1 antagonists for preventing and/or treating pelvi-perineal functional pathological conditions | |
| MA38156B1 (fr) | Utilisation du pidotimod pour traiter la dermatite atopique | |
| EP2858634A4 (fr) | Composés pour le traitement de l'inflammation et de la douleur | |
| EA201200720A1 (ru) | Способ лечения системного слабо выраженного воспаления | |
| FR3005411B1 (fr) | Association d'actifs pour une administration par voie orale pour ameliorer la qualite des ongles. | |
| EA201690070A1 (ru) | Применение аргинина и/или цитруллина для лечения и/или профилактики остеоартроза | |
| FR2976492B1 (fr) | Electrode combinee pour le traitement de l'hyperhidrose axillaire | |
| MA38455B1 (fr) | Utilisation de pidotimodes pour traiter la maladie inflammatoire de l'intestin |